Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat
The Often-Missed Corner of Healthcare That Wall Street Is LovingSubmitted by Nathan Reiff. Publication Date: 3/29/2026. 
Key Points
- Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Elon’s “Hidden” Company
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in this sector to post some of the market's wildest spikes and drops. Investors who want exposure to the healthcare space but worry about that turbulence may prefer a "picks and shovels" approach that focuses on companies providing essential equipment and services, rather than on higher-risk pharmaceutical names. Lab equipment stocks are often overlooked by healthcare investors, even though some companies in this subindustry rank among the largest in the sector. Given the external factors that could shape healthcare in 2026—shifting subsidies, an aging population with greater needs, inflation, the growing role of AI, and more—core lab equipment names may look especially attractive. The companies below are major players worth a closer look. A Recent Dip Masks Thermo Fisher's Long-Term Strengths
A under-the-radar AI stock trading for just $3 could be one of the most overlooked opportunities in the market right now.
While Nvidia dominates headlines, this small-cap play is positioned for significant upside at a fraction of the price.
Discover our No. 1 AI pick before the broader market catches on. Reveal the $3 AI Pick
$182-billion life sciences solutions, diagnostics, and analytical instruments company Thermo Fisher Scientific (NYSE: TMO) has had a difficult start to 2026, with shares down more than 15% year-to-date and the company slipping into TradeSmith's red zone for financial health. A large portion of the recent weakness stems from tariffs and FX volatility, which together shaved more than 100 basis points off margins in 2025. There are several bright spots in Thermo Fisher's recent performance. In Q4 2025, revenue rose to $12.2 billion, up 7% year-over-year, beating analyst expectations by roughly $250 million. Adjusted earnings per share also exceeded estimates at $6.57. That momentum may reflect a string of notable product launches in recent months, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor offerings. Thermo Fisher's broad business mix could provide ample cushion against external pressures. Even if 2026 guidance is modest—revenue is expected to climb 4%–6%—improving EBITDA margins and steady customer demand are supportive. This may explain why analysts remain positive: 17 of 19 analysts rate the stock a Buy or equivalent, and consensus estimates suggest more than 29% upside. Danaher's Business May Be Improving, Even as Guidance Remains ModestDanaher Corp. (NYSE: DHR) shares are down nearly 20% year-to-date, putting the instruments, consumables, and reagents firm in a similar position to Thermo Fisher. Although 2026 guidance calls for modest core revenue growth of 3%–6% year-over-year, the latest quarter showed top- and bottom-line beats, and the company generated $5.3 billion in free cash flow in 2025. Two encouraging areas for 2026 are Danaher's bioprocessing business, which is expected to deliver high-single-digit revenue growth on strong monoclonal antibody demand, and diagnostics. Diagnostics should benefit from recent FDA clearances, and equipment orders appear to be improving after a prolonged downturn, which could help drive further sales growth. Analysts are relatively upbeat on DHR, forecasting about 12.3% earnings growth over the next year and roughly 35% potential upside in the share price. Consequently, 19 of 22 analyst ratings are Buys. Agilent's Biocare Purchase Could Be a CatalystAgilent Technologies (NYSE: A) appears to lag the peers above; its latest earnings showed tepid 4.4% year-over-year revenue growth and slight misses on both revenue and earnings versus expectations. However, the company may have an underappreciated growth catalyst in its recent acquisition of Biocare Medical, which strengthens its position in cancer diagnostics. Although Biocare's price tag—nearly $1 billion—was steep, the deal should add recurring revenue in an area of rising demand. Cancer diagnostics is likely higher-margin than some of Agilent's existing lines and could help lift operating margins, which were 24.6% last quarter. Despite being down roughly 17% year-to-date, analysts see about 42% upside for Agilent shares. Wall Street's consensus is a Moderate Buy overall, with 13 of 16 ratings at Buy or equivalent. |
